THRA

Across TCGA pan-cancer cohorts, THRA mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated THRA data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher THRA mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated THRA expression acts as an unfavorable survival marker.

CCRCC, LSCC, and LUAD are the cancer types where THRA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.550	1.000	.018	5	view →
LSCC	OS	Median	II,III,IV	0.775	1.000	.038	4	view →
LUAD	DFS	Tertile	All	0.516	0.867	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

THRA–CCRCC (DFS)

Open the CCRCC breakdown →